title: Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade.
abstract: The clinical consequences of immune antibodies generated to abciximab (ReoPro) and infliximab (Remicade) are described. Abciximab, a chimaeric Fab fragment that binds to the beta3 integrin of the GPIIb/IIIa and alphavbeta3 receptors on human platelets, is approved in the US and Europe for use in percutaneous coronary intervention (PCI) to prevent cardiac ischaemic complications. The effects of induced antibodies upon the safety and efficacy of repeat administration of abciximab have been evaluated in the ReoPro Re-administration Registry Study, in which 5.7% of patients were HACA positive before re-treatment. An interim evaluation of 1000 patients has indicated that re-administration of abciximab can be accomplished in the setting of PCI with an acceptable safety and efficacy profile. Infliximab is a chimaeric IgG1 antibody specific for human TNFalpha, and is approved in the US and Europe for the acute treatment of the signs and symptoms of Crohn's disease and for the chronic treatment of rheumatoid arthritis (RA). The incidence of antibodies to infliximab is reported to be approximately 10%; however, an inverse dose-immunogenicity relationship was observed, indicating that higher doses of infliximab (> or = 3 to 10 mg/kg) could reduce the incidence of immune antibodies. The induction of immune antibodies could also be reduced by concomitant administration of low-dose methotrexate and other immunosuppressant agents. Although antibodies to infliximab appeared to be associated with lower serum infliximab concentrations and a slightly higher incidence of infusion reactions, these immune antibodies were generally not associated with a reduction in clinical efficacy. In addition, the antibodies induced to infliximab are specific for infliximab, and do not cross-react with other currently available therapeutic antibodies.
authors.affiliation: Centocor, Inc., Malvern, PA 19355, USA. cwagner@cntus.n.com
authors.forename: C L
authors.initials: CL
authors.lastname: Wagner
authors.forename: A
authors.initials: A
authors.lastname: Schantz
authors.forename: E
authors.initials: E
authors.lastname: Barnathan
authors.forename: A
authors.initials: A
authors.lastname: Olson
authors.forename: M A
authors.initials: MA
authors.lastname: Mascelli
authors.forename: J
authors.initials: J
authors.lastname: Ford
authors.forename: L
authors.initials: L
authors.lastname: Damaraju
authors.forename: T
authors.initials: T
authors.lastname: Schaible
authors.forename: R N
authors.initials: RN
authors.lastname: Maini
authors.forename: J E
authors.initials: JE
authors.lastname: Tcheng
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D000069285:Infliximab; D010976:Platelet Count
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007140:Immunoglobulin Fab Fragments; D000069285:Infliximab; D000077284:Abciximab